CYTK Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.55M

-55.38%

-1.431

+13.57%

16.19M

+925.04%

-1.549

+13.9%

19.87M

-70.24%

-1.583

+41.34%

Estimates Revision

The market is revising Downward the revenue expectations for Cytokinetics, Incorporated (CYTK) for FY2025, with the revenue forecasts being adjusted by -3.51% over the past three months. During the same period, the stock price has changed by 2.48%.

Revenue Estimates for FY2025

Revise Downward

-3.51%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+12.57%

In Past 3 Month

Stock Price

Go Up

+2.48%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 81.50 USD with a low forecast of 61.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

61.00

Averages

81.50

High

120.00

Current: 0.000

Low

61.00

Averages

81.50

High

120.00

Leerink

Roanna Ruiz

Outperform

maintain

$73 -> $83

2025-12-22

Reason

Leerink

Roanna Ruiz

Price Target

$73 -> $83

2025-12-22

maintain

Outperform

Reason

Leerink analyst Roanna Ruiz raised the firm's price target on Cytokinetics to $83 from $73 and keeps an Outperform rating on the shares.

Truist

Srikripa Devarakonda

Buy

upgrade

$70 -> $84

2025-12-22

Reason

Truist

Srikripa Devarakonda

Price Target

$70 -> $84

2025-12-22

upgrade

Buy

Reason

Truist analyst Srikripa Devarakonda raised the firm's price target on Cytokinetics to $84 from $70 and keeps a Buy rating on the shares. Following recent approval with a differentiated label, the firm thinks MYQORZO is poised to generate significant revenue in obstructive hypertrophic cardiomyopathy. Truist has updated its model and points out worldwide peak sales for oHCM alone of $3.7B vs. $3.8B consensus. The firm anticipates a steady MYQORZO launch in early 2026 that it believes should perform at least as well as Camzyos's launch.

Morgan Stanley

NULL

Overweight

maintain

$65 -> $71

2025-12-22

Reason

Morgan Stanley

Price Target

$65 -> $71

2025-12-22

maintain

NULL

Overweight

Reason

Morgan Stanley raised the firm's price target on Cytokinetics to $71 from $65 and keeps an Overweight rating on the shares after the FDA approved the company's Myqorzo with "a differentiated label and streamlined REMS." The firm, which is "constructive" on Cytokinetics' ability to execute a strong launch, sees near-term catalysts that could drive additional upside, the analyst tells investors.

BofA

Neutral

maintain

$63 -> $64

2025-12-22

Reason

BofA

Price Target

$63 -> $64

2025-12-22

maintain

Neutral

Reason

BofA raised the firm's price target on Cytokinetics to $64 from $63 and keeps a Neutral rating on the shares after the FDA approved aficamten as Myqorzo. Though calling Friday's approval "a milestone for the company," the firm views the decision and label as in-line with expectations and "thus unlikely to change the debate much," the analyst tells investors.

Leerink

Outperform

maintain

$73 -> $83

2025-12-22

Reason

Leerink

Price Target

$73 -> $83

2025-12-22

maintain

Outperform

Reason

Leerink raised the firm's price target on Cytokinetics to $83 from $73 and keeps an Outperform rating on the shares. The firm is updating its model to reflect the Food and Drug Administration approval of Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy and its incrementally more positive view on Myqorzo's commercial outlook following the differentiated label and Risk Evaluation and Mitigation Strategy profile.

Barclays

Overweight

maintain

$82 -> $87

2025-12-22

Reason

Barclays

Price Target

$82 -> $87

2025-12-22

maintain

Overweight

Reason

Barclays raised the firm's price target on Cytokinetics to $87 from $82 and keeps an Overweight rating on the shares. The firm says Myqorzo received FDA approval in obstructive hypertrophic cardiomyopathy a week ahead of the FDA action date. The label was largely in line with expectations, with flexibility of rapid titration, the analyst tells investors in a research note. Barclays continues to view Myqorzo as the preferred drug over Camzyos.

Valuation Metrics

The current forward P/E ratio for Cytokinetics Inc (CYTK.O) is -10.11, compared to its 5-year average forward P/E of -9.68. For a more detailed relative valuation and DCF analysis to assess Cytokinetics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.68

Current PE

-10.11

Overvalued PE

-7.27

Undervalued PE

-12.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.74

Current EV/EBITDA

-11.16

Overvalued EV/EBITDA

-7.11

Undervalued EV/EBITDA

-12.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

183.03

Current PS

99.16

Overvalued PS

379.90

Undervalued PS

-13.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 5964.05% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CYTK News & Events

Events Timeline

No data

News

7.0

01-02Globenewswire

Cytokinetics Faces Shareholder Investigation Over Alleged Misleading Statements

7.5

2025-12-31Benzinga

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

7.0

2025-12-30Globenewswire

Cytokinetics Faces Shareholder Investigation Over Alleged Misstatements

People Also Watch

Frequently Asked Questions

What is Cytokinetics Inc (CYTK) stock price today?

The current price of CYTK is 62.33 USD — it has decreased -4.72 % in the last trading day.

What is Cytokinetics Inc (CYTK)'s business?

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

What is the price predicton of CYTK Stock?

What is Cytokinetics Inc (CYTK)'s revenue for the last quarter?

Cytokinetics Inc revenue for the last quarter amounts to 1.94M USD, increased 318.14 % YoY.

What is Cytokinetics Inc (CYTK)'s earnings per share (EPS) for the last quarter?

Cytokinetics Inc. EPS for the last quarter amounts to -2.55 USD, increased 87.50 % YoY.

What changes have occurred in the market's expectations for Cytokinetics Inc (CYTK)'s fundamentals?

How many employees does Cytokinetics Inc (CYTK). have?

Cytokinetics Inc (CYTK) has 498 emplpoyees as of January 08 2026.

What is Cytokinetics Inc (CYTK) market cap?

Today CYTK has the market capitalization of 8.00B USD.